ICE Bioscience

Established in Beijing in 2010, ICE Bioscience operates as a contract research organization (CRO) specializing in integrated drug discovery. The company was founded by Yingji Li, who currently serves as the General Manager, and Dr. Li Yan holds the position of Chairman of the Board. Yingji Li brings extensive experience in cardiovascular and central nervous system drug research and development, as well as pharmacology. The firm has positioned itself as a target-driven biology platform, providing services that span the entire preclinical drug discovery process, from target identification and validation to the selection of preclinical candidates.

The company's business model is centered on providing comprehensive, customized solutions to global pharmaceutical companies, biotechnology firms, and research institutions. Revenue is generated by offering a wide array of services that support the development of various drug types, including small molecules, antibodies, ADCs, and PROTACs. ICE Bioscience addresses the needs of its clients for speed, efficiency, and cost-effectiveness in their R&D processes. The company has engaged with over 1,000 global partners and conducts more than 10,000 studies annually.

ICE Bioscience has developed extensive technical platforms to support its service offerings. This includes a target-based drug screening platform with a vast library of over 1,000 targets like kinases and enzymes, more than 100 ion channels, and over 150 GPCRs. The company also operates in vitro and in vivo pharmacology screening platforms for therapeutic areas such as oncology, immunology, cardiovascular diseases, and central nervous system disorders. A significant part of their service includes early-stage druggability assessments, covering DMPK, ADME, and in-vitro safety and toxicology screenings like hERG and kinase panel profiling. Since its inception, the firm has expanded its footprint with laboratories and business centers in Beijing, Shanghai, Xuzhou, Guiyang, and internationally in Singapore and Boston, employing over 400 people.

The company's growth has been supported by several funding rounds. After a Series A funding in 2021, it secured a Series B round in 2022. This was followed by a Series B+ round in 2023 and two more rounds, Series B++ and Series C, in 2024. Key investors include E-Town International Investment, Alwin Capital, Jifeng Ventures, CICC Capital, and Addor Capital.

Keywords: contract research organization, CRO, drug discovery, preclinical services, target validation, lead optimization, pharmacology, oncology, immunology, cardiovascular, central nervous system, DMPK, ADME, in-vitro screening, in-vivo models, ion channel screening, kinase assays, cell-based assays, cardiac safety, pharmacokinetics, integrated drug discovery, biologics services, small molecule development